Please try another search
Nippon Kayaku Co., Ltd., together with its subsidiaries, develops, manufactures, and sells functional chemicals, pharmaceuticals, safety systems, and agrochemicals and other products in Japan and internationally. The company’s Functional and Chemical Business segment offers functional materials, such as epoxy resins, maleimide resins, UV-curable resins, sealants for LCD and LED, maleimide resins, photoresists and insulating materials for micro electro mechanical systems, and cleaning agents and chemicals. This segment provides color materials, including inkjet colorants, industrial inkjet ink, dyes for textiles and papers, and materials for thermal paper; catalysts to produce acrylic and methacrylic acid; and polarizing films, inorganic polarizers, liquid crystal display components and projector parts, and components for x-ray analysis. Its Pharmaceuticals Business segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates of pharmaceuticals, and drugs for diagnosing cancer, as well as GlycoMark, a product as a marker of blood sugar control used for diabetes. The company’s Safety Systems Business segment provides airbag inflators, micro gas generators for seatbelt pretensioners, and squibs. Its Agrochemicals Business segment offers agricultural insecticides, herbicides, soil fumigants, and insanitary insecticides. The company engages in real estate leasing services. The company was formerly known as Nihon Kayaku Seizou Co., Ltd. and changed its name to Nippon Kayaku Co., Ltd. in 1945. Nippon Kayaku Co., Ltd. was incorporated in 1916 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Hiroshi Ota | 56 | 2016 | Independent Outside Director |
Atsuhiro Wakumoto | 66 | 2008 | Chairman & President |
Seiichi Fusamura | 76 | 2020 | Independent Outside Director |
Yasuyuki Fujishima | 76 | 2016 | Independent Outside Director |
Megumi Machida | 62 | 2021 | Full-time Audit & Supervisory Board Member |
Ikuko Akamatsu | 55 | 2023 | Outside Independent Director |
Yoshitsugu Ishida | 66 | 2019 | Representative Executive Vice President & Director |
Shigeyuki Kawamura | 61 | 2021 | MD, Head of Safety Systems Group & Director |
Makoto Takeda | - | 2022 | MD & Director |
Ichiro Wakasa | 69 | 2022 | Outside Audit & Supervisory Board Member |
Shinji Inoue | - | 2023 | MD & Director |
Hiroshi Shimada | - | 2023 | MD, Head of Pharmaceuticals Group & Director |
Kyoichi Toriyama | - | 2024 | Outside Audit & Supervisory Board Member |
Atsushi Iwasaki | - | 2024 | Outside Audit & Supervisory Board Member |
Yoichiro Wada | 62 | 2023 | Full-Time Audit & Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review